The medical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s exhibiting significant promise in clinical trials for managing obesity. Unlike some current weight loss treatments, retatrutide appears to deliver a greater substantial reduction in body mass and enhance metabolic health, particular… Read More